在急性髓性白血病治疗中使用Ivosidenib
Antonella Bruzzese1, Caterina Labanca1, Enrica Antonia Martino1
1Department of Onco-Hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Expert opinion on pharmacotherapy
|October 24, 2023
概括
作为IDH1抑制剂的伊沃西迪尼布在治疗急性髓性白血病 (AML) 中表现有前途,通过诱导分化并提供强大的安全性. 它单独或与化疗一起有效,使其适用于组合疗法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 几十年来,急性髓性白血病 (AML) 的治疗依赖于化疗.
- 最近的进展包括向疗法,如低甲基化剂和小分子.
- 新药包括Bcl2抑制剂venetoclax,FLT3抑制剂,IDH1/IDH2抑制剂和刺途径抑制剂.
研究的目的:
- 审查ivosidenib在AML治疗中的作用.
- 突出其在组合疗法中的有效性,安全性和潜力.
- 讨论克服抵抗的策略.
主要方法:
- 对ivosidenib的临床数据和临床前研究的审查.
- 分析ivosidenib作为IDH1R132抑制剂的作用机制.
- 评估其在单疗法和组合治疗中的安全性和有效性.
主要成果:
- 伊沃西代尼布诱导mIDH1AML爆发的分化.
- 它展示了一个特殊的安全配置文件.
- 临床数据显示单一治疗和组合策略的有效性.
结论:
- 伊沃西登尼布的安全性和有效性使其适合与化疗,低甲基化剂或venetoclax.
- 需要进一步的研究来解决ivosidenib耐药性的问题.
- 伊沃西登尼布在AML治疗方面取得了重大进展.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
19
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
19
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
305
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
305
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


